Thursday, October 1, 2020

Immunotherapy Drug Helping Lung Cancer Patients

photo of immunotherapy vial

The immunotherapy drug Tecentriq (atezolizumab) was approved earlier this year by the U.S. Food and Drug Administration to treat patients with newly diagnosed non-small cell lung cancers (NSCLC), which comprise up to 85% of all lung tumors.



from WebMD Healthhttps://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/article_thumbnails/blog_posts/cancer/metastatic_lung_cancer_blog/1800x1200_metastatic_lung_cancer_blog.jpg https://ift.tt/2GoGlJ9
via IFTTT

Related Posts:

  • Can Some Vaccines Reduce Your Alzheimer’s Risk? Could vaccines play a role in preventing Alzheimer’s disease? Researchers are looking at that question more broadly after finding that the flu and pneumonia vaccines might also help protect against the devastating memory los… Read More
  • COVID Can Harm the Infant Heart Researchers found a 2-month-old baby experienced heart issues similar to those seen in adults. The infant later recovered and was released with no heart medications. from WebMD Healthhttps://img.webmd.com/dtmcms/live/webmd… Read More
  • Financial Missteps Could Signal Future Dementia Older people diagnosed with dementia or Alzheimer's were more likely to miss credit card payments as early as six years before their diagnosis, compared with similar people without dementia (about 8% versus 7%), the research… Read More
  • Pandemic Is Driving U.S. Surge in Cardiac Arrests Tied to Overdose Analyzing data on nearly 26 million EMS calls in 2020, they found that OD-linked cardiac arrests reached a peak in May, when lockdowns began to really take hold across the United States. from WebMD Healthhttps://img.webmd.… Read More
  • Baby Girl Born From Embryo Frozen for 27 Years The baby's birth broke the record for the longest-frozen embryo to result in a live birth, which was held by her older sister, Emma. from WebMD Healthhttps://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/arti… Read More

0 comments:

Post a Comment